Dr. Arnie Oronsky has been with InterWest's life sciences team since 1994.
He is a board member of Amplimmune, Applied Genetic Technologies Corporation (AGTC), Arcion, Drais Pharmaceuticals, Dynavax Technologies (DVAX), Integrated Diagnostics, MacroGenics, RadioRX, TESARO and USDS.
As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Arnie brings a deep understanding of medical research to finding and investing in successful life sciences companies.
Prior to joining InterWest, Arnie was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs.
Arnie received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.
|Apr, 2014||Integrated Diagnostics||$30.25M / Series B||InterWest Partners|
|Sep, 2013||Integrated Diagnostics||$1.5M / Seed||InterWest Partners|
|Nov, 2012||Applied Genetics Technologies Corporation||$37.5M / Series B||InterWest Partners|
|Feb, 2012||Integrated Diagnostics||$10M / Series A (Lead)||InterWest Partners|
|Jun, 2011||TESARO||$101M / Series B||InterWest Partners|
|Oct, 2009||Integrated Diagnostics||$30M / Series A (Lead)||InterWest Partners|
|Jun, 2009||Applied Genetics Technologies Corporation||$11.8M / Venture (Lead)||InterWest Partners|
|Oct, 2006||AkaRx||$2M / Series A||InterWest Partners|
|May, 2006||MacroGenics||$45M / Series C||InterWest Partners|
|May, 2006||AkaRx||$8.05M / Series A||InterWest Partners|
|Jan, 2006||Amplimmune||$20M / Series A||InterWest Partners|
|Aug, 2005||AkaRx||$6.05M / Series A||InterWest Partners|
|Nov, 2003||Applied Genetics Technologies Corporation||$27M / Series B||InterWest Partners|